WithdrawnPhase 4

Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy

Stopped: Investigator decided to stop the study because it was difficult to proceed with the study.

0Started 2015-10

Plain-language summary

Pancreatic ductal adenocarcinoma is the fourth cause of death in the Western world. About 40% of pancreatic cancer patients were diagnosed as locally advanced unresectable status without distant metastasis. Concurrent chemoradiotherapy (CCRT) was a reasonable treatment modality for locally advanced pancreatic cancer. However, several adverse events of chemoradiation could lead unfavorable treatment results, which included unique gastrointestinal (GI) toxicities, such as ulcer and hemorrhage in the stomach and duodenum that are included in the radiation field. According to the study in the investigators hospital, 45% of locally advanced pancreatic cancer patients treated with CCRT suffered from GI ulcers, and among them, 65% of the patients experienced the significant hemorrhage events. Although these GI toxicities, the studies for radioprotective agents were limited. Albis® is a newly developed drug comprised of ranitidine, bismuth and sucralfate. The investigators will investigate the radioprotective effect of Albis® for locally advanced pancreatic cancer patients treated with CCRT.

Who can participate

Age range20 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Older than 20 years old and younger than 80 years old * Pathologically confirmed pancreatic ductal adenocarcinoma (metastatic or locally advanced stage) * ECOG Performance status ≤2 * Scheduled fot concurrent chemoradiation * Adequate liver function (total bilirubin \< 1.5 X the upper limits of normal (ULN), AST and ALT \<3 X UNL, and alkaline phosphatases \< 3 X ULN or \< 5 x ULN in case of liver involvement) * Adequate BM function (WBC ≥ 3,500/µl, absolute neutrophil cell count ≥ 1,500 /µl, platelet count ≥ 100,000/µl) * Not remarkable coagulation profile (PT \< 1.5 international normalized ratio(INR), aPTT \<35 sec) * Subjects who given written informed consent after being given a full description of the study Exclusion Criteria: * Coexisting of other malignancies within 5 years, except squamous cell carcinoma and basal cell carcinoma of the skin * Evidence of distant metastasis, such as liver, peritoneum and brain * history of receiving the chemoradiation for pancreatic cancer in the other hospital * History of receiving the operation which affect the anatomy of upper gastrointestinal tract * Any trouble for examination of upper endoscopy * Evidence of GI ulcers (A1\~H2) on endoscopy before start of chemoradiotherapy. * Use of aspirin, anti-platelet agent, anticoagulation agent, NSAIDs, or glucocorticoid within 1 week or enable to stop the administration (including start during chemoradiation) * Use of PPI, Histamine-2 receptor antagonist, antacid…

What they're measuring

Gastrointestinal ulcer incidence

Timeframe: within 4 weeks from end of chemoradiation

Trial details

NCT IDNCT02570529

SponsorYonsei University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-10